Trial reportBMC psychiatry2026
Effect of iTBS on suicidal ideation and emotion regulation in major depressive disorder: a randomized clinical trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06417437 (New Non-invasive Brain-computer Interface), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
New Non-invasive Brain-computer Interface: Theory, Technology and Application Demonstration - Studies on and Intervention for Depressed People Based on Non-invasive BCI and Application Verification
Who cites it
1 citing paper in PubMed.
- Intermittent theta-burst stimulation versus sham stimulation for suicidal ideation and psychiatric symptoms in depressive disorders: A systematic review and meta-analysis of randomized controlled trials.PCN reports : psychiatry and clinical neurosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) with suicidal ideation (SI) is a psychiatric emergency characterized by high risk and a critical need for timely adjunctive intervention. Traditional antidepressants often exhibit a significant therapeutic lag. This study evaluated the efficacy of a 10-day intermittent theta burst stimulation (iTBS) protocol as an adjunctive neuromodulation strategy to alleviate depressive symptoms and suicidal ideation by restoring emotion regulation capacities.
methodsIn this prospectively registered, randomized, double-blind, sham-controlled clinical trial using a pre-specified 2:1 allocation ratio, 78 patients with MDD and SI were assigned to active iTBS plus stable medication management (n = 52) or matched sham stimulation plus stable medication management (n = 26) for 10 consecutive treatment days. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score. Secondary outcomes included the Beck Scale for Suicide Ideation (BSSI), Hamilton Anxiety Rating Scale (HAMA), and Emotion Regulation Questionnaire (ERQ).
resultsThe iTBS group demonstrated a greater reduction in HAMD-17 scores than the sham group, with a significant Group x Time interaction (F(1, 76) = 117.055, p < .001, partial eta-squared = 0.606). For suicidal ideation, the active iTBS group also showed a larger reduction in BSSI scores (post-treatment between-group comparison, p = .003). iTBS treatment significantly enhanced cognitive reappraisal (F(1, 76) = 51.214, p < .001, partial eta-squared = 0.403), and improvement in cognitive reappraisal was negatively correlated with reduction in depressive severity (r = - .455, p = .001). Improvements in anxiety and sleep quality were also greater after active iTBS, whereas digit-span performance remained comparable between groups.
conclusionA 10-day protocol of active iTBS added to stable medication management was associated with greater baseline-to-post-treatment reductions in depressive symptoms and suicidal ideation, together with improvement in adaptive emotion regulation. Because assessments were performed only at baseline and after treatment, these findings should be interpreted as short-term post-treatment effects rather than evidence of a measured time-to-response trajectory.
trial registrationClinicalTrials.gov identifier NCT06417437; registered before participant recruitment (registration date: 23 April 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.